• A) ONC201 and ONC212 efficacy in AML

    Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia. 

    Michael Andreeff, MD, PhD and Jo Ishizawa, MD, PhD. Department of Leukemia, The University of Texas MD Anderson Cancer Center

    Number: 2562, Link: https://ash.confex.com/ash/2019/webprogram/Paper127101.html

    Sunday, December 8, 2019, 6:00 PM-8:00 PM Hall B, Level 2 (Orange County Convention Center)

    B) ONC201 efficacy in Myelofibrosis

    A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells. 

    Ronald Hoffman, MD, Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai Monday   

    Number: 4201, Link: https://ash.confex.com/ash/2019/webprogram/Paper129017.html                                                                          

    December 9, 2019, 6:00 PM-8:00 PMHall B, Level 2 (Orange County Convention Center)